SCHEMBL25397170

SCHEMBL25397170

COC(=O)c1c(C#N)cc(Cl)nc1Nc1ccc(C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.47
MAPT P10636 4/20 0.47
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
HPGD P15428 5/20 0.42
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 2/20 0.42
CYP1A2 P05177 3/20 0.41
CYP3A4 P08684 3/20 0.41
CYP2C19 P33261 3/20 0.41
TP53 P04637 2/20 0.41
CYP2C9 P11712 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GAA P10253 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
EGFR P00533 1/20 0.38
ERBB2 P04626 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1986224 0.87 FER (0.46) MAPTMEN1KMT2AHPGDALDH1A1
SCHEMBL1987971 0.85 GAA (0.43) KDM4EMAPTHPGDALDH1A1HSD17B10
SCHEMBL1986288 0.82 HPGD (0.39) KDM4EMAPTMEN1KMT2AHPGD
SCHEMBL1987469 0.81 ALDH1A1 (0.48) KDM4EMAPTMEN1KMT2AHPGD
SCHEMBL1986212 0.80 EGFR (0.44) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL20173713 0.80 F11 (0.46) KMT2ANPC1RAB9A
SCHEMBL22475480 0.80 MKNK2 (0.35) KDM4EMAPTMEN1KMT2AHPGD
SCHEMBL1985969 0.79 STK4 (0.42) KDM4EMAPTMEN1KMT2AALDH1A1
SCHEMBL20164942 0.78 ALDH1A1 (0.39) KDM4EMAPTHPGDALDH1A1HSD17B10
SCHEMBL23397916 0.77 KDM4E (0.37) KDM4EMAPTHPGDALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES WELLS THERAPEUTICS, INC. 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN KDM4E 1148/4885MAPT 4621/4885MEN1 2785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.